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Abstract  
From a political and governance perspective Spain is a decentralized country with 17 states [comunidades autónomas] resulting in a 
governmental structure similar to a federal state. The various state regional health services organizational and management structures 
are focused on caring for acute illnesses and are dominated by hospitals and technology. In a review by the Interstate Council, a body 
for intercommunication and cooperation between the state health care services and national government, there is a move to improve 
health care through an integrative approach between specialized care and primary care at the state level. Community pharmacy does 
not appear to have a major role in this review. Primary health care is becoming more important and leading the change to improve the 
roles of the health care teams. Primary care pharmacists as the rest of public health professionals are employed by the respective 
states and are considered public servants. Total health care expenditure is 9.0% of its GDP with the public health sector accounting for 
the 71% and the private sector 29% of this expenditure. Community pharmacy contracts with each state health administration for the 
supply and dispensing of medicines and a very limited number of services. There are approximately 22,000 community pharmacies and 
52,000 community pharmacists for a population of 47 million people. All community pharmacies are privately owned with only 
pharmacists owning a single pharmacy. Pharmacy chain stores are not legally permitted. Community pharmacy practice is based on 
dispensing of medications and dealing with consumer minor symptoms and requests for nonprescription medications although 
extensive philosophical deep debates on the conceptual and practical development of new clinical services have resulted in national 
consensually agreed classifications, definitions and protocolized services. There are a few remunerated services in Spain and these are 
funded at state, provincial or municipal level. There are no health services approved or funded at a national level. Although the 
profession promulgates a patient orientated community pharmacy it appears to be reluctant to advocate for a change in the 
remuneration model. The profession as a whole should reflect on the role of community pharmacy and advocate for a change to 
practice that is patient orientated alongside the maintenance of its stance on being a medication supplier. The future strategic position 
of community pharmacy in Spain as a primary health care partner with government would then be enhanced. 
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INTRODUCTION 
From a political and governance perspective Spain is a 
highly decentralized country organized around 50 provinces 
in 17 States [Comunidades Autónomas], and two 
Autonomous cities, resulting in a governmental structure 
similar to a federal state. Spain has a population of 47 
million people with its gross domestic product (GDP) in 
2019 of EUR 1,244,757million (EUR 26440 per capita). The 
Spanish health care system is organized through a public 
National Health System (NHS) model financed through 
general taxes. Health care is provided through a network of 
hospitals and primary care health centers offering a broad 
portfolio of services with no-copayments except for 
medicines.1 Expenditure in public health care is 6.4% of its 
GDP with the public health sector accounting for the 71% 
and the private sector 29% of this expenditure. The private 
sector is increasing, with almost 20% of the population 
having private insurance.1  
In 2018 total health care expenditures according to Health 
Ministry was EUR 105,000 million/year (9.0% GDP and EUR 
255/pp) distributed in public health care costs of EUR 
74,000 million/year (6.4% of the GDP and EUR 1594/pp) 
and private care costs of EUR 31,000 million/year (2.6% of 
the GDP and EUR 662/pp). Expenditures in the public 
health care was distributed in hospital care (63%), primary 
care (14%), community pharmacy (17%) and others (6%). 
The cost of prescription medicines in community pharmacy, 
financed by the government public health system, was EUR 
12,000 million.2 
The Interstate Council [Consejo Interterritorial] is a body for 
intercommunication and cooperation between the state 
health care services and national government with 
objective of ensuring cohesion of the system and 
guaranteeing citizens’ rights in the whole country.3 Each 
state has its own health ministry [consejería de salud] and 
these are linked to the national Ministry of Health. 
The responsibility for health matters is fundamentally 
transferred from the National government to the states. 
The National government retains the responsibility of 
registering medications and setting the price of 
medications and defining common set of health services to 
which all the population is entitled. These health services 
are defined in the Common Services Portfolio of the 
National Health System [Cartera Común de Servicios del 
Sistema Nacional de Salud] which is subdivided into three 
sections. One of them, Supplementary Common Portfolio 
[Cartera Común Suplementaria], includes the dispensing of 
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medicines. Importantly there are no pharmaceutical 
services incorporated in any of the lists.4 
Primary health care  
The Spanish National Health System, due to its 
decentralized structure and management, faces challenges. 
The system is structurally focused to care for acute illnesses 
and thus is dominated by hospitals and technology. 
However, there is generally acceptance that there is need 
to evolve due to changes in social need, such as aging, 
polypharmacy patient, frailty and vulnerability of the 
population. Defragmentation of the healthcare delivery has 
led to the development of 17 separate and different 
regional health services.5 However, there is a move to 
improve health care through an integrative approach 
between specialized care and primary care at the states 
level. The common objective is to work towards a new 
management model, more horizontal and organized 
around patients with chronic illnesses.1 The system 
currently suffers from 17 different approaches using 
different terminologies.6  
In 2018, the Interstate Council commenced a consultative 
process to design a “Community and Primary Care Strategic 
Framework”.7 State representatives, health care 
professionals, patients and users were invited to participate 
with the aim of improving health care and advance the 
strengthening and leadership of primary health care. The 
Ministry of Health has agreed with the Interstate Council 
proposal to progress towards a more integrated, equitable 
and efficient primary care.8 There is a sense that primary 
health care progressively needs to take the lead, assuming 
a greater importance in the health care system. 
According to the report, primary care has 
disproportionately suffered from the impact of the 2008 
economic crisis and austerity politics, negatively affecting 
the approximately 13,000 primary care health centers. 
Primary health care is organized in various ways within 
states using different terminology and management 
structures although there is a commonly, smaller 
geographical areas usually called basic health zones [zonas 
básicas de salud].9 Health centers are where basic–primary 
health care is provided through “primary health care 
teams”, composed of family physicians, pediatricians, 
gynecologists, nurses, primary care pharmacists, assistants 
and support administrative personnel. All heath care 
professionals are employed by the respective states and 
are considered public servants. 
There are around 750 primary care pharmacists, although 
they are not always located in health centers and not 
widespread. Their role is to improve safety, effectiveness 
and efficiency in the use of medicines and medical devices 
both at an individual or population level. Primary care 
pharmacists hold a strategic position being able to 
coordinate and guaranteeing pharmacotherapy continuity 
along the system and direct patient care activities are 
included in their job profiles.
10
 However, the direct patient 
services for these primary care pharmacists is very limited 
and only occurs in few locations. In the short term, primary 
care pharmacists are expected to coordinate the 
development of multidisciplinary protocols to guarantee 
pharmacotherapy continuity including medication 
reconciliation in care transitions. Currently, there is limited 
collaboration between primary care pharmacists and 
community pharmacy and there is no policy guiding this 
collaboration and it tends to be episodic and sporadic. 
Primary care pharmacists could extend this coordination 
with the establishment of collaboration protocols between 
primary care teams and community pharmacy for 
medication reconciliation, pharmacotherapy optimization, 
improvement of medication safety and effectiveness, 
adherence improvement and reduction of inappropriate 
use of medicines. The potential for extensive collaboration 
has not been explored strategically nor operationally. 
Spanish community pharmacy 
To practice as a pharmacist there is a need to complete a 
five-year university degree resulting in the award of Master 
of Pharmacy (MECES Level 3) meeting European Union 
regulations.11 In addition, to work as a pharmacist dealing 
with patients in any setting, it is compulsory to register in a 
Province Pharmacists’ Association [Colegio Provincial de 
Farmacéuticos]. These Provincial Pharmacists’ Associations 
are members of a national professional association called 
General Council of Province Pharmacists’ Associations 
[Consejo General de Colegios Oficiales de Farmacéuticos] 
which tends to act as the major professional organization 
dealing with central government.12  
There are a number of other organizations which 
represents pharmacy owners [Federación Empresarial de 
Farmacéuticos Españoles] or employees (Unions and a new 
technicians Federation is under way).There is also the 
Spanish Family and Community Pharmacy Society (SEFAC), 
a scientific society which is enthusiastically involved in 
promoting clinical activities in community pharmacies and 
has achieved a good relationship with family physicians 
associations. 
There are approximately 22,000 community pharmacies in 
Spain with an average of 2,117 people per pharmacy the 
lowest ratio in the European Union after Greece.13,14 All 
community pharmacies are privately owned with only 
pharmacists owning a single community pharmacy, 
although more than one pharmacist may jointly own a 
pharmacy. Pharmacy chain stores are not legally permitted. 
The establishment of new pharmacies is controlled by the 
state governments based on two criteria: population per 
pharmacy and distance from another existing pharmacy. 
The minimum population allowed for opening a new 
pharmacy range from 700 to 2,500 in states. The minimum 
distance between the new pharmacy and an existing one 
ranges from 150 to 250 meters.15 In 2018, there were more 
than 74,000 registered pharmacists of whom 
approximately 52,000 work in community pharmacy.13 
There is an average of 2.4 pharmacists per pharmacy. The 
technician workforce is estimated to be around 31,000.16 
In 2019, the average turnover of a community pharmacy 
was EUR 911,740, coming 71% from medicines and 29% 
from consumer health products. The average net margin 
before taxes for a community pharmacy was around 10%.17 
The staff pharmacists’ salary is usually between EUR 25,000 
and EUR 35,000 per year.18 Community pharmacy national 
medication sales in 2019 were estimated to be EUR 15,636 
million corresponding to 1,359 million units. Consumer 
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health products accounted for EUR 6,068.6 million 
corresponding to 557.5 million units. Medications are 
exclusively sold in community pharmacies.  
Community pharmacies are reimbursed by government at a 
margin of about 28% of the pharmacy fixed retail price. The 
price of medications is fixed by the national government 
making it common to all states. This is one of the primary 
responsibilities of the national Government. 
 
COMMUNITY PHARMACY SERVICES 
A national Law 16 passed in 1997 covers specific matters 
related to community pharmacy and is in addition to 
Common Services Portfolio of the National Health 
System.19 The main service in Law 16 covers the 
distribution and supply of medicines. This law also makes it 
compulsory for all Spanish pharmacies to provide patient 
counseling services, medication review with follow-up 
(detecting, preventing, solving negative outcomes of 
pharmacotherapy), compounding, and pharmacovigilance 
(adverse drug reaction reporting system). However, despite 
this law community pharmacy practice is much the same as 
prior to the law being enacted, with an emphasis and focus 
on dispensing of medications and dealing with consumer 
minor symptoms and requests for nonprescription 
medications.  
An important advance in defining direct patient services 
was made in Spain with the publication of a national 
“Consensus on Pharmacy Services”. This statement came 
from an expert panel which met in 2001 under the 
guidance of the Ministry of Health.20 The consensus 
identified and defined three main services to be provided: 
dispensing, minor ailments scheme, and medication review 
with follow up. Dispensing was defined to include the 
provision of the medication with advice to ensure patient 
knowledge and adherence with treatment. Minor ailments 
service covered assisting the patient to choose the 
appropriate nonprescription medication for minor ailment 
and, if necessary, referral to the physician. Medication 
review with follow up covered monitoring a patient’s 
pharmacotherapy to identify, detect, and prevent negative 
clinical outcomes. To follow up on these definitions a 
national group called Pharmaceutical Care Forum was 
established with the support of the Ministry of Health in 
2004. This group confirmed the previous consensus, and 
went onto developing service protocols for these three 
services. It counted with the participation of different 
partners, and published a new Consensus on 
Pharmaceutical Care.21 In 2009, following the completion of 
the work, a Pharmaceutical Care Forum in Community 
Pharmacy [Foro AF-FC] was established with the following 
participants in: General Council of Province Pharmacists’ 
Associations, the Spanish Family and Community Pharmacy 
Society, the postgraduate pharmacy practice group of the 
University of Granada and the Spanish Pharmaceutical Care 
Foundation. From 2012 to 2018, the Clinical Pharmacy and 
Pharmacotherapeutic Unit at the University of Barcelona 
and since 2018, representatives of the Spanish Pharmacy 
Deans Conference. This Forum has updated definitions and 
described, classified and developed various services and 
protocols for community pharmacy services (Table 1).22,23  
In summary, the above-mentioned process has meant the 
pharmacy profession has had extensive philosophical deep 
debates on the conceptual and practical development of 
new clinical services resulting in national consensually 
agreed classifications, definitions and protocolized services. 
However, the practical application to usual day practice has 
been limited with only the passionate, enthusiastic and 
motivated pharmacists taking up the mantle of providing 
services. Even in this group, it has been to a limited number 
of patients and intermittingly, probably attributed to the 
lack of remuneration.  
In addition to the above-mentioned process, research has 
been conducted by various Spanish research groups 
showing that some pharmacy services can achieve positive 
outcomes measured by the ECHO model. Medication 
review with follow up service using the Dáder Method has 
been the most studied service.24-26 The conSIGUE Program, 
promoted by General Council of Province Pharmacists’ 
Associations, has studied the impact and implementation 
of MRF service.27 The impact and implementation of 
Adherence services in community pharmacy, also 
promoted by the General Council, had been investigated 
and continues under research.28,29 SEFAC is also promoting 
research, having participated in an international project 
and undertaken research such as INDICA+PRO evaluating 
the impact and the implementation of a minor ailment 
service co-designed with GPs.30,31 
Remunerated services at a state level  
There are a few remunerated services in Spain and these 
are funded at a states, provincial or municipal level. For all 
these services or programs, a form of accreditation by 
providers is required.  
Methadone supply is quite a common service having 
started in the Basque country in 1995, Cataluña and Aragon 
(1998) and extended to other 7 states. Remuneration 
ranges from EUR 54 to 67 per patient/month. In the Basque 
country there are 890 methadone patients. 
HIV testing which started in the Basque Country in 2009 
and has been subsequently implemented in Cataluña, 
Baleares islands, Cantabria and Castilla y León. Patients pay 
EUR 5, except for Cataluña where the patient pays EUR 10, 
Table 1. Classification of Community Pharmacy services [servicios asistenciales] in community pharmacy agreed by Foro AF-FC 
Pharmaceutical Care Services Community health related services 
Dispensing Health promotion 
Minor ailments Health education 
Reconciliation Health prevention including screening 
Adherence Measurement of clinical parameters 
Home first-aid kit Nutritional advice/counselling 
Compounding Syringe-exchange program 
Medication review Smoking cessation 
Medication information service  
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community pharmacy receiving from the administration a 
payment between EUR 10 and 18 per test. In addition, 
since 2014 in the Basque country a syphilis test is 
performed to men who have had sex with men. To date 
24,602 HIV tests had been performed (since 2009), 2,284 
syphilis tests since 2011.32  
In Cataluña, remunerated services include colorectal cancer 
screening (EUR 1 per test and EUR 10 monthly practice 
allowance).33 Patient group educational program on use of 
medications are also remunerated. Although a sentinel 
pharmacy pharmacovigilance program is undertaken in 
Madrid, Castilla Leon, and Asturias with no payment, in 
Cataluña it is remunerated with approximately 100 
participant pharmacies receiving a practice allowance of 
EUR 1,000 per year.  
In the Basque country there are other drug addiction 
related programs such as state financed anti-HIV kit 
(containing a new syringe, a preservative, a small towel, 
sterile water and a small container to prepare the mixture). 
From 1997 to 2017, 4.66 million kits have been sold at a 
pharmacy charge to the patients of EUR 1. Additionally, 
there is also a syringe exchange program, paid by the state 
at no cost to the patient. In one of the provinces of the 
Basque country there were 18,046 syringe exchanges 
during 2018.34 
Dose administration aids (DAA), preparation of 
multicompartment compliance aids, are very common in 
Spain although, in general, pharmacies do not charge or 
charge a token amount (around EUR 10 per month). There 
are some examples of agreements for DAA services 
between town councils and local pharmacies.35 The first 
such program was a social-health program, remunerated at 
EUR 31.63 patient/month, in the Basque country. Eligible 
patients are part of a municipal social services program. 
The service is provided by community pharmacies and is 
paid by the state health ministry.36  
In Valencia there is a “directly observed treatment” service, 
mainly for tuberculosis treatments, which consists of 
patients taking their medications in the presence of the 
pharmacist who certifies the action.37 This service is being 
reimbursed at EUR 56.06 patients per month), covering all 
observed treatments requested by physicians.  
Most Spanish pharmacies subscribe to a drug-waste 
collection system (SIGRE) in response to European Directive 
94/62 governing container management.38 This service is 
also free, financed by pharmaceutical companies and use 
the wholesalers to manage logistics of discarded medicines. 
In 2019, 102.84 g per person and year were recycled what 
means an increase of 16.12% since 2015.39 
Professional organization strategic plans  
There are no detailed strategic plans from the professional 
organizations. Although general statements of the future of 
the profession are made by professional organizations and 
there is an apparent national, state and local consensus 
that the future of community pharmacy and pharmacist lies 
in patient orientated services. The development of a 
strategic plan for community pharmacy 2020-2030 had 
been announced by the General Council to be presented in 
2020; however, no information is yet available. 
Since 2019 the General Council of Province Pharmacists’ 
Associations, has had a promoting and marketing campaign 
using new branding for the profession “We are 
Pharmacists, We are Patient Carers, We are Socially 
Orientated, We are Digital” [Somos Farmacéuticos, Somos 
Asistenciales, Somos Sociales, Somos Digitales]. A 
significant amount of resources is being devoted to the 
development and use of technology concentrating mostly 
of the projects around a Nodofarma project. Nodofarma is 
an electronic platform whose an objective is to facilitate 
the transformation of the community pharmacy profession. 
The platform, which is an attempt to link the 22,000 
community pharmacies, is composed of a series of 
interconnected services. Programs such as SEVeM (Spanish 
branch of EMVO) to identify and avoid dispensing 
counterfeit medicines, CISMED to analyze in real time 
medication shortages, validation of private prescriptions 
both paper and electronically produced, and Nodofarma 
Asistencial (a networking system to help pharmacists 
implement the nationally agreed professional services). 
Some Province Pharmacists’ Associations have their own 
platforms (i.e. Seville, Valencia) that are envisaged to be 
integrated or interoperable with Nodofarma in a near 
future.  
Concurrently the Spanish Community and Family 
Pharmacists Association (SEFAC), has developed and offers 
its members a service practicing oriented platform called 
SEFAC-eXPERT which provide community pharmacists with 
information technology based service programs and 
protocols. Interestingly at the moment, there is no 
coordination between these two major organizations 
around those projects and there appears to be a 
competitive approach. 
 
CHALLENGES TO THE INTEGRATION OF 
COMMUNITY PHARMACY 
Perspective from the pharmacy organizations  
Despite much debate over the last 10 years with respect to 
the implementation and universality of patient-oriented 
services from community pharmacy, it is reasonable to 
conclude that most of the barriers remain unresolved and 
the implementation of services has not been established in 
a universal way in community pharmacy.40 Critically there is 
lack of payment for services which with a number of other 
factors is essential. Significantly, there appears to be a lack 
of advocacy from the majority of the leadership for changes 
to the current remuneration system and this continuous to 
be a critical factor delaying the implementation of services. 
It is acknowledged that implementation and sustainability 
of services requires profitability, with this issue not 
seeming to be a priority for professional leaders. 
Nevertheless, the discourse of professional pharmacy 
organizational leaders has changed and at present, they are 
publicly promoting and defending a more clinical and 
patient oriented practice through service implementation. 
This discourse, however, is not being followed by a change 
in usual practice by ordinary community pharmacists.  
There is a perception that practicing community 
pharmacists may not yet have a clear understanding of the 
required practice change when researchers and strategists 
talk about a shift from a product to a patient-oriented 
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practice. The political climate of professional pharmacy 
organizations, associated with the facilitation for the 
provision of services, is limited to having a consensus on 
national priority services and to providing excellent 
technology to provide the services. Research has shown 
that service implementation needs well defined services, 
and implementation programs that entails implementation 
indicators and the support of practice change facilitators 
with remuneration to succeed and be 
sustainable.27,29,31,41,42,43 Most of the General Council of 
Province Pharmacists’ Associations and other pharmacy 
organizations efforts to change the current practice of 
community pharmacy are based on strategies that support 
research, educational actions and technology but not the 
critical element of remuneration that might be the catalyst 
for the change of practice. 
Perspective from the health authorities  
Community pharmacy is seen as an external element to the 
system, a private actor and external contractor in a system 
controlled and managed by public authorities. The external 
contractual relationship of community pharmacy, in a 
health care system, that most other health care 
professionals in primary care are employees of the states 
leads to a perception that community pharmacists are 
mainly product providers. Nevertheless, there is a 
recognition that pharmacists are health care professionals, 
well distributed around the country and with a great 
potential. Governments, at different levels, when 
developing policies appear to only have limited 
consideration of the value-add of community pharmacy 
services. At the same time, some administrators and health 
care professionals embedded in the health care system are 
influenced and focus on the commercial elements of 
community pharmacy. They may not be aware or reject the 
potential role of community pharmacy in optimizing 
healthcare outcomes for individual patients and the 
population. It appears that in a competitive environment 
for resources, the economic arguments associated with 
community pharmacy services are rejected. 
Perspective from the other health care professionals  
In the recent past, there have been some controversies 
around nursing profession and community pharmacist 
practicing pharmaceutical care. The nursing profession was 
advocating that certain roles around medication such as 
medication reviews and adherence would be best delivered 
by them. However, at present interprofessional 
relationships have improved and there are good 
interactions and collaboration between pharmaceutical 
organizations, such as the General Council of Province 
Pharmacists’ Associations, SEFAC and some medical 
scientific associations. From a corporative point of view 
there are good relationships with the General Councils of 
medical practitioners and dentists with a number of 
agreements including dealing with electronic private 
prescriptions. The relationship with some GPs associations 
is excellent and there is a yearly conference between SEFAC 
and the Spanish Society of Primary Care Physicians 
(SEMERGEN).44 As an example, a statement in collaboration 
with the Spanish Society of General and Family Physicians 
(SEMG) and SEMERGEN entitled “COVID-19. Problems and 
solutions in Primary Care and Community Pharmacy” has 
been released.45 
Perspective from the patients  
Patients in Spain report being very satisfied and 
comfortable with the current pharmacy service as their 
expectations and needs are being apparently met. Patients 
are generally unaware of the need for professional services 
so their current expectations are fully met. 
Future 
The future integration of community pharmacy in the 
Spanish healthcare system can be said to be dependent on 
several critical factors. These factors include:  
• The development of the strategic review of primary care 
in Strategic Framework for Primary and Community Care 
[Marco estratégico para la Atención Primaria y 
Comunitaria] provides an opportunity for community 
pharmacy to be integrated in primary care. The integration 
of community pharmacy in the system needs to be an 
element of the strategic direction for primary care.  
• The enhancement of the role of primary care pharmacists 
in the collaboration and coordination of community 
pharmacists. Integration with the rest of the health care 
team would be essential.  
• The inclusion of community pharmacy services in the 
Common Services Portfolio would ensure that these 
services are provided to population in all states  
• Following the discourse on the importance of patient 
orientated services from community pharmacy by 
pharmacy political leaders at the state level should be 
focused on the value add and the need to implement 
remunerated services. 
• The profession at all levels commences advocating for the 
remuneration of community pharmacy services. 
• The enhancement of the positive relationship between 
Spanish General Council and SEFAC with primary care 
medical practitioners’ associations. 
Although a number of these factors are external to the 
profession, the major emphasis should be on ensuring that 
the profession as whole reflects on the role of community 
pharmacy and advocates for a change to a practice that is 
patient orientated alongside the maintenance of its stance 
on being a medication supplier. The future strategic 
position of community pharmacy in Spain as a primary 
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